CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond FoFrOwRarWd-ALoRoDkin LgO StOatKeImNeGnt Ss TATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “could,” “may,” “might,” “will,” “likely,” “anticipates ...

公司概况 - Foghorn是一家临床阶段的精准治疗生物技术公司，专注于通过选择性地针对染色质调控系统来纠正异常基因表达，开创一类新药物，治疗癌症和其他疾病[467] 项目进展 - Foghorn自2015年成立以来，已经开发了超过15个项目，目前有两个处于临床阶段的药物候选品，预计在2023年上半年和中期分别获得初步临床数据[470] 合作与合同 - Foghorn与Lilly和Merck签订合作协议，分别获得了3亿美元和1.5亿美元的前期支付，并有望获得未来数十亿美元的里程碑付款和版税[475][486][491] 财务状况 - 公司自成立以来一直未记录任何所得税收益[503] - 截至2022年12月31日，公司联邦和州级净经营亏损结转分别为2.217亿美元和2.033亿美元[504] - 合作收入在2022年12月31日的年度达到1,922.8万美元，较2021年增长了1,790.9万美元[511] - 研发费用在2022年达到1.05618亿美元，较2021年增长了2.5293万美元[513] - 总体而言，公司在2022年度录得净亏损为1.08882亿美元，较2021年度减少了756.2万美元[511] - 利息收入在2022年达到570万美元，较2021年增长了561.6万美元[516] - 公司在2022年度未记录任何利息支出，较2021年度减少了190.6万美元[518] - 公司截至2022年12月31日的现金、现金等价物和可市场交易证券为3.458亿美元[520] - 2022年度公司经营活动提供了1.93612亿美元的现金，主要来源于运营资产和负债的变动[521] - 2022年度公司投资活动中，净现金使用为2.4432亿美元，主要用于购买市场交易证券和购买固定资产[523] - 2021年12月31日，投资活动提供的净现金为3,620万美元，主要是由于市场证券到期139,500万美元，部分抵消了1亿美元的市场证券购买和330万美元的固定资产购买[524] - 2022年12月31日，融资活动提供的净现金为180万美元，主要来自普通股期权行权和员工股票购买计划的净收益[525] - 截至年报中包含的财务报表的发行日期，公司预计现金、现金等价物和市场证券将足以支持至少12个月的运营支出和资本支出需求[527]

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond November 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "l ...

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond September 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," " ...

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond June 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "likel ...

Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases February 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "c ...

Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases September 2021 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in Disclaimer, Confidentiality, and Forward-Looking Statements this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan ...

Targeting the Chromatin Regulatory System Broadening the Impact of Precision Medicines for Oncology and Other Diseases June 2021 Forward-Looking Statements This presentation contains Disclaimer, Confidentiality, and Forward forward-looking statements. All statements other -Looking Statements than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," " ...